Search Result

Results for "

thrombopoietin receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Thrombopoietin Receptor (22) Apoptosis (9) ASK1 (1) Autophagy (1) Bacterial (6) CDK (2) COX (1) Cyclin G-associated Kinase (GAK) (2) Cytochrome P450 (2) ERK (4) Isotope-Labeled Compounds (3) JAK (2) JNK (1) MMP (1) NF-κB (1) p38 MAPK (2) PI3K (2) Reference Standards (6) SOD (1) STAT (6) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (17) Endocrinology (1) Infection (6) Inflammation/Immunology (11)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Targets Recommended: Thrombopoietin Receptor

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-15306

Eltrombopag Maximum Cited Publications 24 Publications Verification SB-497115	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (SB-497115) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-148748

Butyzamide 3 Publications Verification	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-15306A

Eltrombopag Olamine Maximum Cited Publications 24 Publications Verification Eltrombopag diethanolamine salt; SB-497115GR	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-19883

Lusutrombopag 3 Publications Verification S-888711	Thrombopoietin Receptor	Inflammation/Immunology
Lusutrombopag is an orally bioavailable **thrombopoietin (TPO) receptor** agonist, used for treatment of chronic liver disease.

HY-112486

TA-316 Megakaryocytes/platelets inducing agent	Cyclin G-associated Kinase (GAK)	Cardiovascular Disease
TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and **thrombopoietin (TPO) receptor** agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells .

HY-13463

Avatrombopag 5 Publications Verification AKR-501; E5501; YM477	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) is an orally active, nonpeptide **thrombopoietin (TPO) receptor agonist (EC₅₀**=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-122620

Rafutrombopag (tautomerism) Hetrombopag (tautomerism); SHR-8735 (tautomerism)	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

HY-13463A

Avatrombopag maleate 5 Publications Verification AKR-501 maleate; E5501 maleate; YM477 maleate	Thrombopoietin Receptor Cytochrome P450 ERK STAT	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) maleate is an orally active, non-peptide thrombopoietin receptor (TPO receptor) agonist (EC₅₀: 3.3 nM). Avatrombopag maleate mimics the biological activity of TPO. Avatrombopag maleate increases platelet production by activating intracellular signaling systems and promotes the production of platelets and megakaryocytes from hematopoietic precursor cells. Avatrombopag maleate is a substrate for cytochrome P450 (CYP) 2C9 and CYP3A .

HY-145589

Rafutrombopag Hetrombopag; SHR-8735	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology Cancer
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

HY-N1508

Ecliptasaponin A	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .

HY-148748G

Butyzamide	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-13463B

Avatrombopag hydrochloride 5 Publications Verification AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride	Thrombopoietin Receptor	Cardiovascular Disease Cancer
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide **thrombopoietin (TPO) receptor agonist (EC₅₀**=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-15306S

Eltrombopag-13C4 1 Publications Verification SB-497115-¹³C₄	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-112486G

TA-316 (GMP) Megakaryocytes/platelets inducing agent (GMP)	Cyclin G-associated Kinase (GAK)	Cardiovascular Disease
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .

HY-125101A

Rafutrombopag diolamine	Thrombopoietin Receptor	Cardiovascular Disease
Rafutrombopag diolamine is the derivative of Rafutrombopag. Rafutrombopag is a thrombopoietin receptor agonist .

HY-13463BS

Avatrombopag-d8 hydrochloride AKR-501-d8 hydrochloride; E5501-d8 hydrochloride; YM477-d8 hydrochloride	Isotope-Labeled Compounds Thrombopoietin Receptor	Cardiovascular Disease
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463R

Avatrombopag (Standard) AKR-501 (Standard); E5501 (Standard); YM477 (Standard)	Reference Standards Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (Standard) is the analytical standard of Avatrombopag. This product is intended for research and analytical applications. Avatrombopag (AKR-501) is an orally active, nonpeptide **thrombopoietin (TPO) receptor agonist (EC₅₀**=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-15306R

Eltrombopag (Standard) SB-497115 (Standard)	Reference Standards Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Standard) is the analytical standard of Eltrombopag. This product is intended for research and analytical applications. Eltrombopag (SB-497115) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-15306AR

Eltrombopag Olamine (Standard) Eltrombopag diethanolamine salt (Standard); SB-497115GR (Standard)	Reference Standards Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Olamine) (Standard) is the analytical standard of Eltrombopag (Olamine). This product is intended for research and analytical applications. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-14756

Totrombopag	Thrombopoietin Receptor	Others
Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology .

HY-135041

Totrombopag choline SB-559448 choline	Thrombopoietin Receptor	Others
Totrombopag (SB-559448) choline is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag choline initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag choline can be used to study platelet production and megakaryocyte biology .

HY-19883S

Lusutrombopag-d13 S-888711-d₁₃	Isotope-Labeled Compounds Thrombopoietin Receptor	Inflammation/Immunology
Lusutrombopag-d₁₃ is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.

HY-153239

Eltrombopag methyl ester	Thrombopoietin Receptor	Inflammation/Immunology
Eltrombopag methyl ester is a derivative of Eltrombopag, which is a **thrombopoietin (Tpo) receptor** agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia .

HY-19883R

Lusutrombopag (Standard) S-888711 (Standard)	Reference Standards Thrombopoietin Receptor	Inflammation/Immunology
Lusutrombopag (Standard) is the analytical standard of Lusutrombopag. This product is intended for research and analytical applications. Lusutrombopag is an orally bioavailable **thrombopoietin (TPO) receptor** agonist, used for treatment of chronic liver disease.

HY-13463BR

Avatrombopag hydrochloride (Standard) AKR-501 hydrochloride (Standard); E5501 hydrochloride (Standard); YM477 hydrochloride (Standard)	Thrombopoietin Receptor Reference Standards	Cardiovascular Disease Cancer
Avatrombopag (hydrochloride) (Standard) is the analytical standard of Avatrombopag (hydrochloride). This product is intended for research and analytical applications. Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463AR

Avatrombopag maleate (Standard) AKR-501 maleate (Standard); E5501 maleate (Standard); YM477 maleate (Standard)	Thrombopoietin Receptor Cytochrome P450 ERK STAT Reference Standards	Inflammation/Immunology Cancer
Avatrombopag (maleate) (Standard) is the analytical standard of Avatrombopag (maleate). This product is intended for research and analytical applications. Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-W713365

Eltrombopag-d3 SB-497115-d₃	Isotope-Labeled Compounds Thrombopoietin Receptor Apoptosis Bacterial	Infection Cardiovascular Disease Cancer
Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

Art. -Nr.	Produktname	Type

HY-148748G

Butyzamide	Fluorescent Dyes
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

Butyzamide

Fluorescent Dyes

Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-112486G

TA-316 (GMP) Megakaryocytes/platelets inducing agent (GMP)	Fluorescent Dyes
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .

Art. -Nr.	Produktname	Type

HY-148748G

Butyzamide	Biochemical Assay Reagents
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

Butyzamide

Biochemical Assay Reagents

HY-112486G

TA-316 (GMP) Megakaryocytes/platelets inducing agent (GMP)	Biochemical Assay Reagents
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-N1508

Ecliptasaponin A	Triterpenes other families Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .

Species:	Rat (2)
Tag:	His (1) Fc (1)
Source:	HEK293 (1) Sf9 insect cells (1)

Art. -Nr.	Compare	Produktname	Species	Source	Image

HY-P74244

	C-MPL Protein, Rat (HEK293, Fc) CD110; c-Mpl; MPL; MPLV; thrombopoietin R; TPO-R	Rat	HEK293
	The C-MPL Protein, a receptor for thrombopoietin, is a protein encoded in humans by the oncogene of myeloproliferative leukemia virus. The C-MPL Protein is involved in the activation of the JAK/STAT/MAPK signaling pathway. C-MPL Protein is a biomarker for thrombocytopenia. C-MPL Protein, Rat (HEK293, Fc) is the recombinant rat-derived C-MPL protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74243

	C-MPL Protein, Rat (sf9, His) CD110; c-Mpl; MPL; MPLV; thrombopoietin R; TPO-R	Rat	Sf9 insect cells
	The C-MPL Protein, a receptor for thrombopoietin, is a protein encoded in humans by the oncogene of myeloproliferative leukemia virus. The C-MPL Protein is involved in the activation of the JAK/STAT/MAPK signaling pathway. C-MPL Protein is a biomarker for thrombocytopenia. C-MPL Protein, Rat (sf9, His) is the recombinant rat-derived C-MPL protein, expressed by Sf9 insect cells , with C-His labeled tag.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Art. -Nr.	Produktname	Chemical Structure

HY-15306S

Eltrombopag-13C4 1 Publications Verification
Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

Eltrombopag-13C4

1 Publications Verification

Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-13463BS

Avatrombopag-d8 hydrochloride
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

Avatrombopag-d8 hydrochloride

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-19883S

Lusutrombopag-d13
Lusutrombopag-d₁₃ is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.

HY-W713365

Eltrombopag-d3
Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

Eltrombopag-d3

Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

Host:	Mouse (2) Rabbit (2)
Reactivity:	Human (4) Rat (2) Mouse (2)
Application:	WB (2) FC (2) ELISA (2)
Isotype:	IgG (2) IgG2a (2)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Art. -Nr.	Compare	Produktname	Application	Reactivity	Image

HY-P82496

	Thrombopoietin Receptor Antibody (YA2241) MPL; TPOR; thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110	WB	Human, Mouse, Rat
	Thrombopoietin Receptor Antibody (YA2241) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Thrombopoietin Receptor.

HY-P82496A

	Thrombopoietin Receptor Antibody (YA2241)(PBS only) MPL; TPOR; thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110	WB	Human, Mouse, Rat
	Thrombopoietin Receptor Antibody (YA2241) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Thrombopoietin Receptor.

HY-P84297

	Thrombopoietin Receptor Antibody (YA3994) MPL; MPLV; TPOR; C-MPL; THCYT2	FC, ELISA	Human
	Thrombopoietin Receptor Antibody (YA3994) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Thrombopoietin Receptor.

HY-P84297A

	Thrombopoietin Receptor Antibody (YA3994)(PBS only) MPL; MPLV; TPOR; C-MPL; THCYT2	FC, ELISA	Human
	Thrombopoietin Receptor Antibody (YA3994) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Thrombopoietin Receptor.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Targets Recommended: Thrombopoietin Receptor

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-148748G

Butyzamide	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

thrombopoietin receptor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Natural
Products